NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

Uncoordinated price cuts across the EU are contributing to medicine shortages and driving manufacturers towards more ...

The amended product information will provide more specific detail on encephalitis as a known adverse reaction to ...

The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s ...

In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally ...

People of a certain age may remember Merthiolate and Mercurochrome in the household medicine chest. Whenever someone skinned ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...

New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE ...

JHU's Neurofibromatosis Therapeutic Acceleration Program celebrated the 10th anniversary of its Francis S. Collins Scholars ...

Biodegradable weekly implant delivers stable levodopa levels, aiming to streamline Parkinson’s care while reshaping drug ...

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in ...

Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.